What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

(2023) Alvar Agustí et al.   EUROPEAN RESPIRATORY JOURNAL

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

(2023) Antonio Anzueto et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD

(2023) James F Donohue et al.   International Journal of Chronic Obstructive Pulmonary Disease

Novel Anti-Inflammatory Approaches to COPD

(2023) Mario Cazzola et al.   International Journal of Chronic Obstructive Pulmonary Disease

Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?

(2022) Mario Cazzola et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review

(2021) Luigino Calzetta et al.   International Journal of Chronic Obstructive Pulmonary Disease

Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis

(2021) Mark J. Turner et al.   PHARMACOLOGY & THERAPEUTICS

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD

(2019) Mario Cazzola et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma

(2019) Leif Bjermer et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD

(2018) Dave Singh et al.   EUROPEAN RESPIRATORY JOURNAL

An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD

(2018) Mario Cazzola et al.   EUROPEAN RESPIRATORY JOURNAL

The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia

(2016) Mark J. Turner et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility

(2016) R Venkatasamy et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways

(2015) Luigino Calzetta et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases

(2014) Katharine H. Abbott-Banner et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

CFTR: cystic fibrosis and beyond

(2014) M. A. Mall et al.   EUROPEAN RESPIRATORY JOURNAL

Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

(2014) Clive P. Page   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Cigarette smoke and CFTR: implications in the pathogenesis of COPD

(2013) Andras Rab et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

(2013) Lui G Franciosi et al.   Lancet Respiratory Medicine